卡培他滨和雷替曲塞分别联合贝伐珠单抗治疗晚期结直肠癌的疗效及安全性比较

目的:探讨卡培他滨和雷替曲塞分别联合贝伐珠单抗对晚期结直肠癌患者疗效及安全性的影响。方法:回顾性分析我院2014年1月至2018年12月收治的晚期结直肠癌患者共147例临床资料，其中采用卡培他滨联合贝伐珠单抗治疗77例设为对照组，采用雷替曲塞联合贝伐珠单抗治疗70例设为观察组；比较两组近期疗效、随访生存情况及不良反应发生情况。结果:两组ORR和DCR比较差异无显著性（P＞0.05）；两组中位PFS和OS比较差异无显著性（P＞0.05）；观察组I-II级恶心呕吐、周围神经毒性及手足综合征发生率均显著低于对照组（P＜0.05）；同时观察组III-IV级手足综合征发生率显著低于对照组（P＜0.05）。结论:相较于卡培他滨，雷替曲塞联合贝伐珠单抗治疗晚期结直肠癌可获得相近疾病控制和生存获益，同时还有助于减轻药物不良反应，提高治疗耐受性。

Comparison of efficacy and safety of capecitabine and raltitrexed separately combined with bevacizumab in the treatment of advanced colorectal cancer

Objective:To investigate the influence of capecitabine and raltitrexed separately combined with bevacizumab on clinical efficacy and safety of patients with advanced colorectal cancer.Methods:Clinical data of 147 patients with advanced colorectal cancer were chosen in the period from January 2014 to December 2018 in our hospital and divided into 2 groups including control group (77 patients) with capecitabine combined with bevacizumab and observation group(70 patients) with raltitrexed combined with bevacizumab,and the short-term clinical efficacy,survival time with follow-up and adverse reactions occurrence of 2 groups were compared.Results:There was no significant difference in the ORR and DCR between 2 groups （P＞0.05）.There was no significant difference in the median PFS and OS between 2 groups （P＞0.05）.The incidences of nausea and vomiting,peripheral neurotoxicity and hand foot syndrome for grade I-II of observation group were significant lower than control group（P＜0.05）.The incidence of hand foot syndrome for grade III-IV of observation group was significant lower than control group（P＜0.05）.Conclusion:Compared with capecitabine,raltitrexed combined with bevacizumab in the treatment of patients with advanced colorectal cancer possess the same disease control effects and survival benefit and can efficiently relieve adverse drug reactions and improve treatment tolerance.